CMTX BIOTECH, INC.

KINGS PARK, NY

OncologyPhase I

What changed

Phase I trial registered: Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

4w agoTrial registeredJun 17, 2026Source filing (opens the source filing in a new tab)

Momentum

80no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

453 pre-ticker oncology companies at Phase I

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
NA registered
May 20, 2025
Dyslipaemia · COMPLETED · sponsor: Gdansk University of Physical Education and Sport · Effect of Adding Additional Elastic Band Resistance Training to Waltz Dance on Dyslipidemia in Middle-aged and Elderly Women: a Randomized Controlled Trial
ClinicalTrials.gov · NCT06985550 (opens the source filing in a new tab)
Grant
R42 · $887k · non-dilutive
Mar 1, 2025
CMTX BIOTECH, INC. · PI KOLLISCH-SINGULE, MICHAELA CHRISTINA · NHLBI · award ends Feb 28, 2028 · Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome
NIH RePORTER · NIH RePORTER 10950503 (opens the source filing in a new tab)
Grant
R21 · $246k · non-dilutive
Jun 18, 2024
GEORGE WASHINGTON UNIVERSITY · PI LUO, JIE · NIAID · award ends Oct 31, 2025 · Antigen-Specific Immunosuppression of Myasthenia Gravis by CAR-Engineered Tregs
NIH RePORTER · NIH RePORTER 11121075 (opens the source filing in a new tab)
Trial
PHASE1 registered
Aug 10, 2023
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic NUT Carcinoma, Unresectable Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable NUT Carcinoma · RECRUITING · sponsor: National Cancer Institute (NCI) · Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
ClinicalTrials.gov · NCT05372640 (opens the source filing in a new tab)
Grant
R01 · $526k · non-dilutive
May 1, 2023
SYRACUSE UNIVERSITY · PI MONROE, MARY BETH · NHLBI · award ends Apr 30, 2028 · Shape Memory Polymer Foams for Hemorrhage Control in Traumatic Wounds
NIH RePORTER · NIH RePORTER 11093441 (opens the source filing in a new tab)
Grant
R01 · $380k · non-dilutive
Aug 1, 2005
UNIVERSITY OF IOWA · PI LUO, JIA · NIAAA · award ends Mar 31, 2028 · Endoplasmic Reticulum Stress and Alcohol Neurotoxicity
NIH RePORTER · NIH RePORTER 11054577 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75principal investigator LUO, JIE is named on this company's filings
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the grant record at 0.25no candidate cleared the review threshold

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase I trial registered: Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
4w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
4w agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Effect of Adding Additional Elastic Band Resistance Training to Waltz Dance on Dyslipidemia in Middle-aged and Elderly Women: a Randomized Controlled Trial
5mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Effect of Adding Additional Elastic Band Resistance Training to Waltz Dance on Dyslipidemia in Middle-aged and Elderly Women: a Randomized Controlled Trial
5mo agoTrial completedSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Shape Memory Polymer Foams for Hemorrhage Control in Traumatic Wounds
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Endoplasmic Reticulum Stress and Alcohol Neurotoxicity
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Antigen-Specific Immunosuppression of Myasthenia Gravis by CAR-Engineered Tregs
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R42 · $0.9M · Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome
Feb 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

NA registered

R42 · $887k · non-dilutive

R21 · $246k · non-dilutive

PHASE1 registered

R01 · $526k · non-dilutive

R01 · $380k · non-dilutive